Patents by Inventor Vinod VATHIPADIEKAL

Vinod VATHIPADIEKAL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240132894
    Abstract: Among other things, the present disclosure provides designed oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide improved single-stranded RNA interference and/or RNase H-mediated knockdown. Among other things, the present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and/or internucleotidic linkages) or patterns thereof, conjugation with additional chemical moieties, and/or stereochemistry [e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages)], and/or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., RNA interference (RNAi) activity, stability, delivery, etc.
    Type: Application
    Filed: September 29, 2022
    Publication date: April 25, 2024
    Inventors: Chandra Vargeese, Naoki Iwamoto, David Charles Donnell Butler, Subramanian Marappan, Genliang Lu, Jason Jingxin Zhang, Vinod Vathipadiekal, Maria David Frank-Kamenetsky, Luciano Henrique Apponi, Young Jin Cho
  • Publication number: 20240109931
    Abstract: Among other things, the present disclosure provides designed APOC3 oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide improved single-stranded RNA interference and/or RNase H-mediated knockdown. Among other things, the present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and/or internucleotidic linkages) or patterns thereof, conjugation with additional chemical moieties, and/or stereochemistry [e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages)], and/or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., RNA interference (RNAi) activity, stability, delivery, etc.
    Type: Application
    Filed: October 4, 2022
    Publication date: April 4, 2024
    Inventors: Chandra Vargeese, Naoki Iwamoto, David Charles Donnell Butler, Subramanian Marappan, Genliang Lu, Jason Jingxin Zhang, Vinod Vathipadiekal, Maria David Frank-Kamenetsky, Luciano Henrique Apponi, Hanna Maria Wisniewska-wrona, Xiayun Cheng, Young Jin Cho
  • Publication number: 20230203484
    Abstract: The present disclosure provides double stranded oligonucleotides, compositions, and methods relating thereto. The present disclosure encompasses the recognition that structural elements of double stranded oligonucleotides, such as base sequence, chemical modifications (e.g, modifications of sugar, base, and/or internucleotidic linkages) or patterns thereof, and/or stereochemistry (e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages)), and/or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g, RNA interference (RNAi) activity, stability, delivery, etc. The present disclosure also provides methods for treatment of diseases using provided double stranded oligonucleotide compositions, for example, in RNA interference.
    Type: Application
    Filed: May 24, 2021
    Publication date: June 29, 2023
    Applicant: WAVE LIFE SCIENCES LTD.
    Inventors: Chandra VARGEESE, Naoki IWAMOTO, Luciano H. APPONI, David Charles Donnell BUTLER, Pachamuthu KANDASAMY, Subramanian MARAPPAN, Snehlata TRIPATHI, Wei LIU, Mugdha BEDEKAR, Vinod VATHIPADIEKAL
  • Publication number: 20230145795
    Abstract: Among other things, the present disclosure provides RHO oligonucleotides, compositions, and methods. In some embodiments, provided oligonucleotides comprise nucleobase modifications, sugar modifications, internucleotidic linkage modifications and/or patterns thereof, and have improved properties, activities and/or selectivities. In some embodiments, the present disclosure provides RHO oligonucleotides, compositions and methods for preventing and/or treating RHO-related conditions, disorders or diseases, such as retinopathy (e.g, retinal degeneration, retinal degenerative disease, retinal degenerative disorder, inherited retinal degenerative disorder, retinitis pigmentosa, autosomal dominant retinitis pigmentosa, etc.).
    Type: Application
    Filed: April 24, 2020
    Publication date: May 11, 2023
    Inventors: Michael John Byrne, Vinod Vathipadiekal, Naoki Iwamoto, Chandra Vargeese, Lankai Guo, Andrew Guzior Hoss
  • Patent number: 11603532
    Abstract: Among other things, the present disclosure provides designed oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide improved single-stranded RNA interference and/or RNase H-mediated knockdown. Among other things, the present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and/or internucleotidic linkages) or patterns thereof, conjugation with additional chemical moieties, and/or stereochemistry [e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages)], and/or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., RNA interference (RNAi) activity, stability, delivery, etc.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: March 14, 2023
    Assignee: WAVE LIFE SCIENCES LTD.
    Inventors: Chandra Vargeese, Naoki Iwamoto, David Charles Donnell Butler, Subramanian Marappan, Genliang Lu, Jason Jingxin Zhang, Vinod Vathipadiekal, Maria David Frank-Kamenetsky, Luciano Henrique Apponi, Young Jin Cho
  • Patent number: 11597927
    Abstract: Among other things, the present disclosure provides designed PNPLA3 oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide improved single-stranded RNA interference and/or RNase H-mediated knockdown. Among other things, the present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and/or internucleotidic linkages) or N patterns thereof, conjugation with additional chemical moieties, and/or stereochemistry [e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages)], and/or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., RNA interference (RNAi) activity, stability, delivery, etc.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: March 7, 2023
    Assignee: WAVE LIFE SCIENCES LTD.
    Inventors: Chandra Vargeese, Naoki Iwamoto, David Charles Donnell Butler, Subramanian Marappan, Genliang Lu, Jason Jingxin Zhang, Vinod Vathipadiekal, Luciano Henrique Apponi, Hanna Maria Wisniewska, Xiayun Cheng, Young Jin Cho
  • Publication number: 20210198305
    Abstract: Among other things, the present disclosure provides designed APOC3 oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide improved single-stranded RNA interference and/or RNase H-mediated knockdown. Among other things, the present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and/or internucleotidic linkages) or patterns thereof, conjugation with additional chemical moieties, and/or stereochemistry [e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages)], and/or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., RNA interference (RNAi) activity, stability, delivery, etc.
    Type: Application
    Filed: June 1, 2018
    Publication date: July 1, 2021
    Inventors: Chandra Vargeese, Naoki Iwamoto, David Charles Donnell Butler, Subramanian Marappan, Genliang Lu, Jason Jingxin Zhang, Vinod Vathipadiekal, Maria David Frank-Kamenetsky, Luciano Henrique Apponi, Hanna Maria Wisniewska, Xiayun Cheng, Young Jin Cho
  • Publication number: 20200190515
    Abstract: Among other things, the present disclosure provides designed PNPLA3 oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide improved single-stranded RNA interference and/or RNase H-mediated knockdown. Among other things, the present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and/or internucleotidic linkages) or patterns thereof, conjugation with additional chemical moieties, and/or stereochemistry [e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages)], and/or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., RNA interference (RNAi) activity, stability, delivery, etc.
    Type: Application
    Filed: June 1, 2018
    Publication date: June 18, 2020
    Inventors: Chandra Vargeese, Naoki Iwamoto, David Charles Donnell Butler, Subramanian Marappan, Genliang Lu, Jason Jingxin Zhang, Vinod Vathipadiekal, Luciano Henrique Apponi, Hanna Maria Wisniewska, Xiayun Cheng, Young Jin Cho
  • Publication number: 20200157545
    Abstract: Among other things, the present disclosure provides designed oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide improved single-stranded RNA interference and/or RNase H-mediated knockdown. Among other things, the present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and/or internucleotidic linkages) or patterns thereof, conjugation with additional chemical moieties, and/or stereochemistry [e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages)], and/or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., RNA interference (RNAi) activity, stability, delivery, etc.
    Type: Application
    Filed: June 1, 2018
    Publication date: May 21, 2020
    Applicants: WAVE LIFE SCIENCES LTD., WAVE LIFE SCIENCES LTD.
    Inventors: Chandra Vargeese, Naoki Iwamoto, David Charles Donnell Butler, Subramanian Marappan, Genliang Lu, Jason Jingxin Zhang, Vinod Vathipadiekal, Maria David Frank-Kamenetsky, Luciano Henrique Apponi, Young Jin Cho
  • Publication number: 20190264267
    Abstract: Among other things, the present disclosure pertains to methods and compositions related to phasing of allelic variants of genetic loci. Phasing of allelic variants of genetic loci on an individual patient's chromosomes is highly valuable for many purposes, including patient stratification for allele-specific therapeutics.
    Type: Application
    Filed: July 24, 2017
    Publication date: August 29, 2019
    Applicant: Wave Life Sciences Ltd.
    Inventors: Hailin YANG, Aaron Jay MORRIS, Vinod VATHIPADIEKAL